

Remarks

This is a response to the Restriction Requirement of September 30, 2009. Applicant elects without traverse to prosecute Group I comprising Claims 1-17 drawn to 3,6-substituted pyran of claim 1 wherein B is an optionally substituted phenyl.

New claim 25 which falls into the elected groups is presented for examination.

Applicant has amended the claims to perfect the present election. Moreover, claim 1 is amended to specifically exclude the compounds of the Zhang reference set forth in the Restriction Requirement. It should be pointed out that compound 7a of the Zhang reference exhibits a rather weak inhibition of the dopamine, serotonin and norepinephrine transporters as set forth in Table 2 of that article. This is to be contrasted to the stronger inhibition exhibited by the compounds of the invention as exemplified by the specific compound set forth in claim 25 which is referred to as compound D-161. (see for example, A. K. Dutta et al., *D-161, a novel pyran-based triple monoamine transporter blocker: Behavioral pharmacological evidence for antidepressant-like action*, European Journal of Pharmacology 589 (2008) 73–79 (attached as Exhibit A)). In particular, the compound of claim 25 has extremely low affinity constants for DAT uptake, SERT uptake, and NET uptake. It should be pointed out that the lower the affinity constant the stronger the binding of a ligand to a target receptor protein which in this case are DAT, SERT and NET uptake receptors. Besides extremely high uptake inhibition affinity of 25 for all three transporters, this compound has also exhibited potent *in vivo* activity in animal studies indicating its potential antidepressant activity.

The Petition fee of \$65.00 is being charged to Deposit Account No. 02-3978 via electronic authorization submitted concurrently herewith. The Commissioner is hereby authorized to charge any additional fees or credit any overpayments as a result of the filing of this paper to Deposit Account No. 02-3978.

Prompt and favorable consideration of this application is requested. If the Examiner notes any minor errors, the Examiner is invited to telephone the undersigned so that the matter can be promptly handled by Examiner's amendment.

Respectfully submitted,

ALOKE K. DUTTA

By: /James W. Proscia/

James W. Proscia

Reg. No. 47,010

Attorney/Agent for Applicant

Date: November 30, 2009

BROOKS KUSHMAN P.C.

1000 Town Center, 22nd Floor

Southfield, MI 48075-1238

Phone: (248) 358-4400

Fax: (248) 358-3351